The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder

European Group for the Study of Resistant Depression (GSRD) — Where have we gone so far: Review of clinical and genetic findings

(2012) Alexandra Schosser et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression

(2012) Julien Mendlewicz et al.   NEUROSCIENCE LETTERS

Declining Autopsy Rates and Suicide Misclassification

(2011) Nestor D. Kapusta   ARCHIVES OF GENERAL PSYCHIATRY

Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder

(2011) Alberto Chiesa et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

The size and burden of mental disorders and other disorders of the brain in Europe 2010

(2011) H.U. Wittchen et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder — A European Multicenter Study

(2011) A. Schosser et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism

(2011) Stefano Porcelli et al.   Expert Opinion on Drug Metabolism & Toxicology

High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders

(2011) E M Peñas-Lledó et al.   MOLECULAR PSYCHIATRY

Genome-Wide Association Study of Antidepressant Treatment-Emergent Suicidal Ideation

(2011) Andreas Menke et al.   NEUROPSYCHOPHARMACOLOGY

CYP2D6and the severity of suicide attempts

(2011) Eva M Peñas-Lledó et al.   PHARMACOGENOMICS

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011

(2011) C. Hiemke et al.   PHARMACOPSYCHIATRY

A genomewide linkage study on suicidality in major depressive disorder confirms evidence for linkage to 2p12

(2010) Amy W. Butler et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system

(2010) Magnus Ingelman-Sundberg et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Pharmacogenetics of antidepressive treatment

(2010) Astrid Zobel et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?

(2010) Ari Illi et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response

(2010) Ming-Hsien Tsai et al.   PHARMACOGENOMICS

High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases

(2009) A L Zackrisson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The role of pharmacogenetics in the treatment of depression and anxiety disorders

(2009) Alexandra Schosser et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

(2009) Alessandro Serretti et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Suicide

(2009) Keith Hawton et al.   LANCET

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update

(2008) Edoardo Spina et al.   CLINICAL THERAPEUTICS

How can we realize the promise of personalized antidepressant medicines?

(2008) Florian Holsboer   NATURE REVIEWS NEUROSCIENCE

Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample

(2008) Eric J. Peters et al.   PLoS One